Mallinckrodt, a global specialty pharmaceutical company, has awarded a $3m Healthcare Advancement Grant to Children's National Health System, which is an exclusive provider of pediatric care in the Washington, DC, area.
This supports a three-year outcomes research initiative focused on pediatric patients in the intensive care setting.
In the US, 20% of hospitalised children are cared for in the pediatric intensive care unit (ICU). Yet this is an under-researched patient population with layers of complexity. These patients face a 2.5 to 5% mortality rate, with 5 to 10% serious morbidity rate, and the morbidity and mortality rates double within three years.
The health system is home to the Children's Research Institute and the Sheikh Zayed Institute for Pediatric Surgical Innovation, and is one of the nation's top National Institute of Health (NIH)-funded pediatric institutions.
It is a member of the Collaborative Pediatric Critical Care Research Network of the NIH and has strong partnerships with major universities in the Washington, DC, area, providing data-generation resources.
The institution intends to mine data from different sources and more to unearth knowledge and improve outcomes.
Children's National has identified three priorities to launch and execute this multi-year initiative, specifically establish a Critical Care Outcomes Research Initiative team, build on existing partnerships and expand to acquire additional data, and build outcomes research studies in the critical care arena.